Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Celator(R) Pharmaceuticals Selected to Participate in NCI's Nanotechnology Characterization Laboratory Assay Cascade for Characterization of Nanoparticle Prodrug Delivery Platform

Abstract:
Celator Pharmaceuticals today announced that the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), operated by SAIC-Frederick (Frederick, Maryland), has agreed to conduct characterization studies to advance the development of the company's nanoparticle drug formulation technology.

Celator(R) Pharmaceuticals Selected to Participate in NCI's Nanotechnology Characterization Laboratory Assay Cascade for Characterization of Nanoparticle Prodrug Delivery Platform

Princeton, NJ | Posted on February 17th, 2010

The agreement is part of the NCI's Advanced Technology Partnerships Initiative, which aims to accelerate the delivery of new products to cancer patients through the strategic application of advanced technologies and effective translational research partnerships.

The current material transfer agreement focuses on Celator's hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation to support an eventual investigational new drug (IND) filing with the U.S. Food and Drug Administration. Specifically, the NCL has selected HDPN for intensive physical characterization, in-vitro studies, and in-vivo pharmacology and toxicology protocols.

HDPN is the result of collaboration with Princeton University and subsequent discovery and research efforts at Celator. The technology belongs to a proprietary nanoparticle prodrug delivery platform with broad potential applicability in cancer and other diseases. Docetaxel is a type of taxane drug that is widely used to treat a range of cancers including lung, breast, and prostate.

Celator scientists have demonstrated the HDPN formulation substantially increases drug circulation lifetime and efficacy compared to conventional docetaxel formulations. These improvements formed the basis of the decision made by the NCL's scientific review committee for the characterization study of HDPN.

"Our approach to delivering taxanes such as docetaxel differs from most in that we make the drug more hydrophobic thereby allowing the nanoparticle-incorporated prodrug to circulate in the blood for days after injection," said Dr. Lawrence Mayer, president and head of research of Celator Pharmaceuticals. "Our studies have shown that keeping the drug circulating for extended times correlates with the ability to induce regression of solid tumors to below detectable limits."

"We are pleased the NCL is conducting this work to help us advance HDPN toward the clinic," said Scott Jackson, chief executive officer of Celator Pharmaceuticals. "The technology has broad potential application in addressing therapeutic needs and HDPN represents our first approach."

####

About Celator Pharmaceuticals
Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two Phase 2 products; CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage compound, CPX-571 (a liposomal formulation of irinotecan:cisplatin); and multiple research programs, including the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation. Based on the applications of CombiPlex and the proprietary nanoparticle prodrug delivery platform, Celator is positioned to advance a broad pipeline of cancer therapies involving both previously approved and novel drug agents.

For more information, please visit the company's website at www.celatorpharma.com.

Information on ongoing trials is available at www.clinicaltrials.gov.

For more information, please click here

Contacts:
Celator Pharmaceuticals, Inc.
303B College Road East
Princeton, NJ 08540
USA
Telephone: (609) 243-0123
Fax: (609) 243-0202

Celator Pharmaceuticals Corp.
1779 West 75th Avenue
Vancouver, BC V6P 6P2
Canada
Telephone: (604) 708-5858
Toll-free: (866) 708-5858
Fax: (604) 708-5883

Copyright © PrNewswire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

March 2016; 6th Int'l Conference on Nanostructures in Iran July 29th, 2015

Non-Enzyme Sensor Determines Level of Blood Sugar July 29th, 2015

Flexible Future of Point-of-Care Disease Diagnostic July 29th, 2015

Meet the high-performance single-molecule diode: Major milestone in molecular electronics scored by Berkeley Lab and Columbia University team July 29th, 2015

Nanomedicine

March 2016; 6th Int'l Conference on Nanostructures in Iran July 29th, 2015

Non-Enzyme Sensor Determines Level of Blood Sugar July 29th, 2015

Flexible Future of Point-of-Care Disease Diagnostic July 29th, 2015

Stretching the limits on conducting wires July 25th, 2015

Announcements

Non-Enzyme Sensor Determines Level of Blood Sugar July 29th, 2015

Flexible Future of Point-of-Care Disease Diagnostic July 29th, 2015

Meet the high-performance single-molecule diode: Major milestone in molecular electronics scored by Berkeley Lab and Columbia University team July 29th, 2015

Detecting small metallic contaminants in food via magnetization: A practical metallic-contaminant detecting system using three high-Tc RF superconducting quantum interference devices (SQUIDs) July 29th, 2015

Nanobiotechnology

New computer model could explain how simple molecules took first step toward life: Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules July 28th, 2015

Spintronics: Molecules stabilizing magnetism: Organic molecules fixing the magnetic orientation of a cobalt surface/ building block for a compact and low-cost storage technology/ publication in Nature Materials July 25th, 2015

Programming adult stem cells to treat muscular dystrophy and more by mimicking nature July 22nd, 2015

Biophotonics - Global Strategic Business Report 2015 July 21st, 2015

Alliances/Trade associations/Partnerships/Distributorships

Liquipel Debuts Eyesight-Saving ION-Glass Blue Light Protection for iPhones and Androids at RadioShack Stores Nationwide: Liquipel's Unique Protective Screen, Available at RadioShack, Cuts Harmful Blue Light Implicated in Macular Degeneration by 10x July 28th, 2015

Dais Analytic's Business Affiliate in China Announces Ten-Year Strategic Energy Efficiency Business Arrangement With COFCO: Dais Beijing to Perform Feasibility Study on Over 80 Buildings to Improve Efficiencies as Part of Overall Hotel Energy-Savings Project July 23rd, 2015

Leti and Diabeloop Project Aims at Developing Artificial Pancreas for Diabetes Treatment July 22nd, 2015

Imec and Panasonic Demonstrate Breakthrough RRAM Cell July 16th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project